Renal dysfunction in cirrhosis is not just a vasomotor nephropathy

Kidney International

Volumn 87, Issue 3, 2015, Pages 509-515

  Adebayo, Danielle ^a   Morabito, Vincenzo ^a   Davenport, Andrew ^b   Jalan, Rajiv ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

cirrhosis; hepatorenal syndrome; renal failure

Indexed keywords

INTERLEUKIN 17; TOLL LIKE RECEPTOR 4; BILE ACID; BILIRUBIN; TLR4 PROTEIN, HUMAN;

ABDOMINAL PRESSURE; BACTERIAL INFECTION; BILE CAST NEPHROPATHY; BILE DUCT DISEASE; COMORBIDITY; DISEASE ASSOCIATION; HEPATORENAL SYNDROME; HISTOPATHOLOGY; HUMAN; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FAILURE; LIVER CIRRHOSIS; NONHUMAN; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PRIORITY JOURNAL; REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TRADITIONAL MEDICINE; UPREGULATION; VASOMOTOR DISORDER; VASOMOTOR NEPHROPATHY; ADRENERGIC SYSTEM; BLOOD; COMPLICATION; INFECTION; INFLAMMATION; INTRAABDOMINAL HYPERTENSION; METABOLISM; RENAL INSUFFICIENCY;

BILE ACIDS AND SALTS; BILIRUBIN; HUMANS; INFECTION; INFLAMMATION; INTERLEUKIN-17; INTRA-ABDOMINAL HYPERTENSION; LIVER CIRRHOSIS; RENAL INSUFFICIENCY; TOLL-LIKE RECEPTOR 4; VASOMOTOR SYSTEM;

EID: 84938419433     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.338     Document Type: Short Survey

References (71)

1. Planas R, Montoliu S, Balleste B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006; 4: 1385-1394
2. Papper S, Belsky JL, Bleifer KH. Renal failure in Laennec's cirrhosis of the liver. I. Description of clinical and laboratory features. Ann Inter Med. 1959; 51: 759-773
3. Goresky CA, Kumar G. Renal failure in cirrhosis of the liver. Can Med Assoc J. 1964; 90: 353-356
4. Iwatsuki S, Popovtzer MM, Corman JL, et al. Recovery from "hepatorenal syndrome" after orthotopic liver transplantation. N Engl J Med. 1973; 289: 1155-1159
5. Koppel MH, Coburn JW, Mims MM, et al. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functionalnature of renal failure in advanced liver disease. N Engl J Med. 1969; 280: 1367-1371
6. Salerno F, Gerbes A, Gines P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007; 56: 1310-1318
7. Gines P, Guevara M, Arroyo V, et al. Hepatorenal syndrome. Lancet. 2003; 362: 1819-1827
8. Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut. 2013; 62: 131-137
9. Daugherty NA, Hammond KB, Osberg IM. Bilirubin interference with the kinetic Jaffe method for serum creatinine. Clin Chem. 1978; 24: 392-393
10. Lolekha PH, Jaruthunyaluck S, Srisawasdi P. Deproteinization of serum: another best approach to eliminate all forms of bilirubin interference on serum creatinine by the kinetic Jaffe reaction. J Clin Lab Anal. 2001; 15: 116-121
11. Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis. 2003; 41: 269-278
12. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007; 11: R31
13. Wong F, Nadim MK, Kellum JA, et al. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut. 2011; 60: 702-709
14. Piano S, Rosi S, Maresio G, et al. Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol. 2013; 59: 482-489
15. Fagundes C, Barreto R, Guevara M, et al A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol. 2013; 59: 474-481
16. Wong F, O'Leary JG, Reddy KR, et al. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology. 2013; 145: e1281
17. Barreto R, Fagundes C, Guevara M, et al. Type-1 hepatorenal syndrome associated with infections in cirrhosis. Natural history, outcome of kidney function and survival. Hepatology. 2013; 59: 1505-1513
18. Fagundes C, Pepin MN, Guevara M, et al. Urinary neutrophil gelatinaseassociated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol. 2012; 57: 267-273
19. Epstein M, Berk DP, Hollenberg NK, et al. Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med. 1970; 49: 175-185
20. Blendis L, Wong F. The hyperdynamic circulation in cirrhosis: an overview. Pharmacol Ther. 2001; 89: 221-231
21. Ring-Larsen H. Renal blood flow in cirrhosis: relation to systemic and portal haemodynamics and liver function. Scand J Clin Lab Invest. 1977; 37: 635-642
22. Krag A, Bendtsen F, Henriksen JH, et al. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut. 2010; 59: 105-110
23. Solis-Herruzo JA, Duran A, Favela V, et al. Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome. J Hepatol. 1987; 5: 167-173
24. Stadlbauer V, Wright GA, Banaji M, et al. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology. 2008; 134: 111-119
25. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999; 29: 1690-1697
26. Velez JC, Nietert PJ. Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. Am J Kidney Dis. 2011; 58: 928-938
27. Mindikoglu AL, Dowling TC, Wong-You-Cheong JJ, et al A pilot study to evaluate renal hemodynamics in cirrhosis by simultaneous glomerular filtration rate, renal plasma flow, renal resistive indices and biomarkers measurements. Am J Nephrol. 2014; 39: 543-552
28. Nazar A, Pereira GH, Guevara M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2010; 51: 219-226
29. Fabrizi F, Dixit V, Martin P. Meta-Analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther. 2006; 24: 935-944
30. Garg H, Kumar A, Garg V, et al. Clinical profile and predictors of mortality in patients of acute-on-chronic liver failure. Dig Liver Dis. 2012; 44: 166-171
31. Olson JC, Wendon JA, Kramer DJ, et al. Intensive care of the patient with cirrhosis. Hepatology. 2011; 54: 1864-1872
32. Thabut D, Massard J, Gangloff A, et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology. 2007; 46: 1872-1882
33. Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology. 1994; 20: 1495-1501
34. Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013; 144: 1426-1437
35. Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-Term survival in severe acute alcoholic hepatitis: a double-blind, placebocontrolled trial. Gastroenterology. 2000; 119: 1637-1648
36. Mookerjee RP, Sen S, Davies NA, et al. Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. Gut. 2003; 52: 1182-1187
37. Ernst E. Pentoxifylline for intermittent claudication A critical review. Angiology. 1994; 45: 339-345
38. Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol. 2011; 55: 315-321
39. Wadei HM, Mai ML, Ahsan N, et al. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol. 2006; 1: 1066-1079
40. Fukui H, Matsumoto M, Bode C, et al. Endotoxaemia in patients with liver cirrhosis and upper gastrointestinal bleeding: detection by the chromogenic assay with plasma Tween 80 pretreatment. J Gastroenterol Hepatol. 1993; 8: 577-581
41. Clemente C, Bosch J, Rodes J, et al. Functional renal failure and haemorrhagic gastritis associated with endotoxaemia in cirrhosis. Gut. 1977; 18: 556-560
42. Fernandez J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007; 133: 818-824
43. Mandal AK, Lansing M, Fahmy A. Acute tubular necrosis in hepatorenal syndrome: an electron microscopy study. Am J Kidney Dis. 1982; 2: 363-374
44. Kanel GC, Peters RL. Glomerular tubular reflux-A morphologic renal lesion associated with the hepatorenal syndrome. Hepatology. 1984; 4: 242-246
45. Shah N, Mohamed FE, Jover-Cobos M, et al. Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis. Liver Int. 2013; 33: 398-409
46. Rivera-Huizar S, Rincon-Sanchez AR, Covarrubias-Pinedo A, et al. Renal dysfunction as a consequence of acute liver damage by bile duct ligation in cirrhotic rats. Exp Toxicol Pathol. 2006; 58: 185-195
47. Shah N, Dhar D, El Zahraa Mohammed F, et al. Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression. J Hepatol. 2012; 56: 1047-1053
48. Jo SK, Cha DR, Cho WY, et al. Inflammatory cytokines and lipopolysaccharide induce Fas-mediated apoptosis in renal tubular cells. Nephron. 2002; 91: 406-415
49. Rector WG Jr., Kanel GC, Rakela J, et al. Tubular dysfunction in the deeply jaundiced patient with hepatorenal syndrome. Hepatology. 1985; 5: 321-326
50. Gungor G, Ataseven H, Demir A, et al. Neutrophil gelatinase-Associated lipocalin in prediction of mortality in patients with hepatorenal syndrome: a prospective observational study. Liver Int. 2013; 34: 49-57
51. Nadim MK, Genyk YS, Tokin C, et al. Impact of the etiology of acute kidney injury on outcomes following liver transplantation: acute tubular necrosis versus hepatorenal syndrome. Liver Transplant. 2012; 18: 539-548
52. Marik PE, Wood K, Starzl TE. The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol, Dial, Transplant. 2006; 21: 478-482
53. Bird GL, Sheron N, Goka AK, et al. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med. 1990; 112: 917-920
54. Gonwa TA, Morris CA, Goldstein RM, et al. Long-Term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome-experience in 300 patients. Transplantation. 1991; 51: 428-430
55. Angeli P, Sanyal A, Moller S, et al. Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites. Liver Int. 2013; 33: 16-23
56. Cazzaniga M, Dionigi E, Gobbo G, et al. The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. J Hepatol. 2009; 51: 475-482
57. Davis CL, Gonwa TA, Wilkinson AH. Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation. Part I. Liver Transplant. 2002; 8: 91-109
58. Yan CG, Zhu DF, Wang F. [Study on the expressions and roles of renal heat shock protein 72 and Toll-like receptor 4 in hepatorenal syndrome in rat]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2007; 19: 731-734
59. Park SW, Kim M, Brown KM, et al. Paneth cell-derived interleukin-17A causes multiorgan dysfunction after hepatic ischemia and reperfusion injury. Hepatology. 2011; 53: 1662-1675
60. Takahashi N, Vanlaere I, de Rycke R, et al. IL-17 produced by Paneth cells drives TNF-induced shock. J Exp Med. 2008; 205: 1755-1761
61. Betjes MG, Bajema I. The pathology of jaundice-related renal insufficiency: cholemic nephrosis revisited. J Nephrol. 2006; 19: 229-233
62. Gollan JL, Billing BH, Huang SN. Ultrastructural changes in the isolated rat kidney induced by conjugated bilirubin and bile acids. Br J Exp Pathol. 1976; 57: 571-581
63. Song J, Chang A. Jaundice-Associated acute kidney injury. NDT Plus. 2009; 2: 82-83
64. van Slambrouck CM, Salem F, Meehan SM, et al. Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction. Kidney Int. 2013; 84: 192-197
65. Fickert P, Krones E, Pollheimer MJ, et al. Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice. Hepatology. 2013; 58: 2056-2069
66. Cade R, Wagemaker H, Vogel S, et al. Hepatorenal syndrome. Studies of the effect of vascular volume and intraperitoneal pressure on renal and hepatic function. Am J Med. 1987; 82: 427-438
67. Umgelter A, Reindl W, Wagner KS, et al. Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial. Crit Care. 2008; 12: R4
68. Chang Y, Qi X, Li Z, et al. Hepatorenal syndrome: insights into the mechansims of intra-Abdominal hypertension. Int J Clin Exp Pathol. 2013; 6: 2523-2528
69. Cabrera J, Falcon L, Gorriz E, et al. Abdominal decompression plays a major role in early postparacentesis haemodynamic changes in cirrhotic patients with tense ascites. Gut. 2001; 48: 384-389
70. Salerno F, Guevara M, Bernardi M, et al. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int. 2010; 30: 937-947
71. Carl DE, Ghosh S, Cheng J, et al. Post-paracentesis circulatory derangements are related to monocyte activation. Liver Int. 2013; 34: 1001-1007